SlideShare a Scribd company logo
1 of 47
Type 2 Diabetes and Cancer
Dr. Manel Mata
Family Physician. La Mina Primary Care Centre. Barcelona Family and Community
Medicine Teaching Unit. Catalonian Institute of Health.
DAP_Cat Group. Institut Universitari d’Investigació en Atenció Primaria IDIAP-Jordi Gol.
Barcelona. Spain.
RedGDPS (Spanish Network of Primary Care Groups for the Study of Diabetes).
www.Redgdps.org
Type 2 Diabetes and Cancer
Dr. Manel Mata
Conflict of interest disclosure:
Honoraria from ASTRA-ZENECA, BAYER, BOEHRINGER INGELHEIM, BMS,
ESTEVE, GSK, LILLY, MENARINI, MERCK, MSD, NOVARTIS, NOVONORDISK,
SANOFI and SERVIER for the participation in Advisory Boards and lectures
about the treatment of diabetes.
• The relationship between diabetes
and cancer
• Does antidiabetic treatment have an
influence on the risk of cancer ?
Type 2 Diabetes and cancer
American Diabetes Association
American Cancer Society
Giovanucci E et al. Diabetes Care. 2010;33(7):1674-85.
T2DM is associated with increased risk for some cancers (liver, pancreas,
endometrium, colorectal, breast, bladder) and reduced risk for prostate
Garg SK et al. Diabetes, Obesity and Metabolism. 2014; 16: 97-110
Increased risk of cancer in diabetic patients
Summary of cohorts and case control studies meta-analysis
Liver 2.5
Pancreas 2.6
Endometrium 2.2
Breast 1.3
Prostate 0.9
Garg SK et al. Diabetes, Obesity and Metabolism. 2014;16:97-110
Men Women
All 1.44 1.35
Liver 5.16 6.37
Pancreas 1.67 2.13
Breast -- 1.65
Prostate 1.30 --
Increased cancer mortality
in diabetic patients
There are numerous considerations when assessing cancer
risk between diabetics and non diabetics:
• Some cancers of metabolically active organs, such liver and
pancreas, may induce the onset of type 2 diabetes
•The general pattern of an initial elevated peak in cancer risk
at the time of diabetes onset, which is substantially higher
than subsequent risk, suggests that many cancers are being
diagnosed at or around the time of recognition of diabetes
Johnson JA et al. Diabetologia 2012; 55:1607–18
Walker JJ et al. Lancet Diabetes Endocrinol 2013; 1: 132–39
Timing of exposure: reverse causality and detection bias
Reports from two different population databases have shown an initial
spike in the risk of most cancers immediately after the onset of
diabetes, followed by a subsequent normalisation of risk
1. Investigation of early cancer symptoms leads to the diagnosis of
diabetes (reverse causality)
2. Diagnosis of diabetes can lead to additional clinical investigations,
resulting in the identification of cancers (bias in cancer detection)
3. Reverse causality and bias in cancer detection might also be present
in the time of initiation for a new drug.
Cancer Incidence
excluding 1st year
aRR
Liver 3.50
Pancreas 2.85
Colon 1.56
Breast 1.56
Bladder 0.53
Prostate 0.76
Kidney 0.25
Tayside (Scotland) DART MEMO database
9,577 newly diagnosed T2DM 1993–2004,
19,154 matched non-diabetic comparators
National Cancer Register.
No significant differences in
Any cancer 1.05 (0.93-1.18)
Ogunleye AA, Ogston SA, Morris AD, Evans JMM
Diabetes and Cancer
share common risk factors
• Non-modifiable: Aging, Male sex, Race/Ethnicity
• Modifiable:
Obesity
Diet (high calories, red meat, processed foods...)
Sedentarism
Smoking habit
Excessive alcohol consumption
Giovannucci E, et al. Diabetes Care 2010; 33: 1674-85
The relationship between type 2
diabetes and cancer is consistent
and reasonably strong.
Johnson JA & Pollak M. Diabetologia. 2010;53:2086-8
American Diabetes Association
American Cancer Society
Biological links between
Diabetes and Cancer
• Hyperinsulinemia
• Hyperglycaemia
• Chronic inflammation (citokines)
• Insulin receptor/insulin-like growth factor I (IGF-I) Axis
– Promotion of cell proliferation
– Decreased apoptosis
Giovannucci E et al. Diabetes Care 2010; 33: 1674-85
American Diabetes Association
American Cancer Society
Garg SK et al. Diabetes, Obes and Metab. 2014; 16: 97-110
The accumulation of experimental
and epidemiological evidence is more
consistent with the hyperinsulinaemia
hypothesis and less so with the
hyperglycaemia hypothesis.
Johnson JA & Pollak M. Diabetologia. 2010;53:2086-8
Obesity and Endometrial Cancer
https://tginnovations.wordpress.com/2013/08/10/you-already-know-how-to-defeat-cancer/
• The relationship between diabetes and
cancer
• Does antidiabetic treatment have an
influence on the risk of cancer ?
Type 2 Diabetes and cancer
Antidiabetic drugs and cancer
- Metformin neutral or protective
Safety signals:
- Sulfonylureas colon
- Insulin pancreas, colon
- Pioglitazone bladder
- Sitagliptin and Exenatide pancreas
- Dapagliflozin bladder
Although still limited, early evidence suggests that metformin is
associated with a lower risk of cancer and that exogenous
insulin is associated with an increased cancer risk.
Further research is needed to clarify these issues and evaluate
if insulin glargine is more strongly associated with cancer risk
compared with other insulins.
Giovanucci E et al. Diabetes Care. 2010;33(7):1674-85.
Considerations when comparing users vs non users:
• Confounding by indication: the non-random allocation of all
glucose-lowering therapies in observational studies
• Accounting for total, and perhaps cumulative drug exposure
• Immortal time bias: the period between cohort entry and
date of first exposure, during which cancer has not occurred,
is misclassified or excluded (not accounted for in the analysis)
Johnson JA et al. Diabetologia 2012; 55:1607–18
Several observational studies indicate that T2D patients treated
with metformin have a lower risk of cancer, but these should be
interpreted with caution because of possible confounders, mostly
notably confounding by indication.
Smith U & Gale EAM. Diabetologia 2010; 53:1541–4
Data from Ranzomized Clinical Trials (meta-analysis)
• Improving blood glucose control confers no benefit in cancer risk.
• UKPDS 34 reported a not statistically significant 29% reduction in
cancer mortality rates with metformin.
Johnson JA & Bowker SL et al Diabetologia 2011; 54:25–31
Metformin and cancer
Metformin was associated with reduced risk (OR 0.38), while insulin
(OR 4.99) and insulin secretagogues (OR 2.52) with increased risk
of pancreatic cancer in diabetic patients.
Li D et al. Gastroenterology 2009;137:482–8
Case-control study 2004 to 2008
973 pancreatic cancer (259 DM)
863 controls (109 DM. Texas (US)
Insulin (HR 1.26) and sulfonylureas (HR 1.38)
were associated with increased cancer risk in
comparison to metformin, but this differences
disapeared after several adjustments
Kowall B et al. Diabetes Care 2015 ; 38:59-65
SU and insulin vs metformin
German database. N=22,556, 4.8 years
Sulfonylureas vs No SU
ADOPT trial 1.17 (ns)
6 Cohort studies 1.19 (ns)
10 Case-control studies 1.05 (ns)
Thakkar B et al. Metabolism 2013; 62:922-34
Metformin vs No Metformin
ADOPT trial 1.01 (ns)
9 Cohort studies 0.85 (ns)
13 Case-control studies 0.71 (0.57-0.88)
Thakkar B et al. Metabolism 2013; 62:922-34
Our results show that metformin may reduce cancer
incidence and mortality in patients with diabetes.
However, the reduction seems to be of modest
magnitude and not affecting all populations equally.
Gandini S et al. Cancer Prev Res 2014; 7(9); 867–85
47 studies (65,540 cancers)
Metformin vs No Metformin
0.690.90
0.660.45
Provinciali N et al. Expert Opin. Drug Saf. 2015; 14(10):1573-1585
Metformin acts as a mitochondrial
poison inhibiting complex 1of the
mitochondrial respiratory chain.
Mitochondrial ATP production is
impaired, creating a state of
energy restriction.
Provinciali N et al. Expert Opin. Drug Saf. 2015; 14(10):1573-1585
Epidemiologic data support the conclusion that metformin has beneficial
anticancer effects in diabetics or subjects with high BMI or insulin
resistance.
Thus far, the evidence from clinical trials stems largely from modulation of
biomarkers in a direction consistent with benefit, that is, decreased
proliferation or increased apoptosis, in breast and endometrial cancers.
Multiple trials are ongoing and should inform the field as to whether this
potential anti-cancer agent truly has benefit.
Insulin and cancer
Bowker SL et al. Diabetes Care 2006; 29(2):254-8
10.309 T2DM starting sulfonylurea, metformin or insulin monotherapy
Saskatchewan database (Canada) 1991-1996. Mean follow-up: 5,4 years (range 1-9)
Adjusted HR by age, sex and commorbidity (Chronic Disease Score)
Greater cancer mortality with sulfonylureas (1.3)
and insulin (1.9) in comparison to Metformin
Currie C et al. J Clin Endocrinol Metab 2013; 98: 668–77
UK General Practice Research
Database, 2000–2010
84,622 T2DM patients
Conclusions:
Exogenous insulin therapy was associated with an increased risk
of diabetes-related complications, cancer (OR 1.81), and all-cause
mortality (OR 2.2).
Differences in baseline characteristics between treatment groups should
be considered when interpreting these results.
Men Women
Increased mortality in diabetic patients with cancer
(greater in those treated with insulin)
Conclusions/interpretation:
More intensive diabetes treatment
reflects a larger degree of
comorbidity at the time of cancer
diagnosis and a poorer survival
noDM
DM no Med
DM+OHA
DM+INS
RR 6.5
426,129 patients
with incident cancer,
(42,205 with
diabetes prior to
cancer diagnosis)
DM+INS
RR 5
Ranc K et al. Diabetologia 2014; 57:927-34
The link beetween exogenous insulin and cancer:
Insulin has affinity for the IGF-1 receptors expressed by
tumor cells
Increased insulin, IGF-1, and IGF-2 signaling through the insulin receptor and
IGF-1 receptor can induce tumorigenesis by up-regulating the insulin receptor
and IGF-1 receptor signaling pathways
Gallagher EJ et al. Endocr Pract. 2010;16(5):864-873.
2009 Insulin Glargine and cancer
Diabetologia, 26 june 2009
Five original papers and one
editorial about cancer and glargine
ORIGIN Glargine vs. Standard Care
• 1st CV Composite: HR = 1.02 (0.94, 1.11)
• 2nd CV Composite: HR = 1.04 (0.97, 1.11)
• Death: HR = 0.98 (0.90, 1.08)
• Microvascular Composite: HR = 0.97 (0.90, 1.05)
• Cancer: HR = 1.00 (0.88, 1.13)
• Conversion IFG/IGT to DM: HR = 0.72 (0.58, 0.91) P=0.006
N=12,537; 573 sites; 40 countries; Median Follow-up: 6.2 years
The ORIGIN trial Investigators. 10.1056/NEJMoa1203858 en NEJM.org
Outcome Reduction with Initial Glargine INtervention
Owens DR. Diabetes Care 2012; 35:2426-8
On the basis of the findings from
epidemiological studies and
the latest pharmacokinetic data
the chapter on whether insulin
glargine per se is an independent
risk factor for cancer should now
be closed.
17.9.10 FDA alert
9.6.11 Withdrawal in France and Germany
15.6.11 FDA Warning
21.7.11 EMA Warning
……….
5.12.14 Observational study of 6 population
databases (5,9 M patients-year): No increase
2010
Pioglitazone and bladder cancer
N= 1,491,060, 40-79 year-old T2DM on antidiabetic treatment,
155,535 on Pioglitazone. Follow-up 42 months (2006-2009)
175 bladder cancer cases in Pio users vs 1,841 in nonPio users
49.4 vs 42.8 per 100,000 person-years (aRR 1.22)
HR
Any exposure 1.22
Exposure >24 months 1.36
Cumulative dose >28,000 mg 1.75
EMA 21/07/11
• The benefits outweigh the risks in those patients responding well to pioglitazone
• After three to six months of treatment, discontinue pioglitazone in patients not
having sufficient benefit
• Discontinue treatment with pioglitazone in those patients who have, or have had,
bladder cancer, include those who are awaiting investigation of haematuria.
Neumann A et al. Diabetologia 2012; 55:1953-62
Observational study of 6 population
databases (5.9 M patient-years)
3,248 incident bladder cancer cases
RR (95% CI)*
Pioglitazone
Men 1.01 (0.97-1.06)
Women 1.04 (0.97-1.11)
Rosiglitazone
Men 1.01 (0.98-1.03)
Women 1.00 (0.94-1.07)
*adjusted for age, calendar year, diabetes duration,
smoking and any ever use of the drug
There was no evidence for any association between
cumulative exposure to pioglitazone and bladder
cancer in men (HR 1.01) or in women (RR 1.04) after
adjustment for age, calendar year, diabetes duration,
smoking, and any ever use of pioglitazone.
Levin D. Diabetologia. 2015 Mar;58(3):493-504.
Diabet Med. 2015;32(3):305-13.
2013
Incretins and pancreas cancer
Butler P & Gale E
Nauck M
Diabetes Care Publish Ahead of Print,
published online May 6, 2013
To date, the FDA has not seen a
convincing signal between the use of
GLP-1 or DPP-4 agents and pancretic
cancer, but it continues to monitor new
findings and carefully evaluates them.
JUNE 2013
Incretins and Pancreatic Ductal Adenocarcinoma
One study of eight necropsies (7 sitagliptin and 1 exenatide) described
enlargement of the pancreas, chronic inflammation and dysplasia
(premalignant) that might favor the long term appearance of ductal cancer
Butler AE et al. Diabetes 2013; 62: 2595-604
Plausible model:
Stimulation of GLP1 receptors might proliferate exocrine ducts accelerating
dysplasia in patients with a chronic low-grade pancreatic inflammation
Butler A & Gale E, Diabetes Care. published online May 6, 2013
The FDA and the EMA agree that assertions concerning a
causal association between incretin-based drugs and
pancreatitis or pancreatic cancer, as expressed recently in the
scientific literature and in the media, are inconsistent with the
current data.
Egan AG et al. NEJM 2014; 370(9) Pub Online 27 february 2014
TECOS (Sitagliptin)3
Placebo
n=7,339
Sitagliptin
n=7,332
p value
Pancreatic cancer 14 (0.2%) 9 (0.1%) 0.32
DPP4 inhibitors in the cardiovascular outcomes trials
Pancreas cancer
SAVOR TIMI53 (Saxagliptin)2 Placebo
(N=8,212)
Saxagliptin
(N=8,280)
p value
Cancer (%) 4.4 4.0 0.15
Pancreatic Cancer, n (%) 12 (0.1) 5 (0.06) 0.095
EXAMINE (Alogliptin)1 No pancreatic cancer cases in both arms
1. White et al. NEJM 2013 2. Scirica et al. NEJM 2013 3. Green et al. NEJM 2015
http://professional.diabetes.org/Presentations_Details.aspx?session=4740
ELIXA study lixisenatide vs placebo
Pancreatic neoplasm during the study
n (%)
Placebo
N=3032
Lixisenatide
N=3031
Events adjudicated as malignant by PSAC
Patients with events
Related
Possibly related
Unlikely related
Not related
9 (0.3)
0
2 (<0.1)
3 (<0.1)
4 (0.1)
3 (<0.1)
0
0
2 (<0.1)
1 (<0.1)
Events adjudicated as benign by PSAC
Patients with events 0 1 (<0.1)
Events with insufficient documentation
Patients with events 1 (<0.1) 1 (<0.1)
PSAC, Pancreatic Safety Assessment Committee
Dapagliflozin and bladder cancer
Malignancy (continued)
*Incidence rate ratio = 1.047 (95% CI: 0.702, 1.579)
DAPA=dapagliflozin
Johnsson K et al. Diabetologia 2012;55(Suppl1)743-P
SGLT2 inhibitors (Dapagliflozin) and risk of cancer
EMA 12/11/12
A causal relationship between dapagliflozin and bladder
cancer is unlikely.
As a precautionary measure, dapagliflozin is not
recommended for use in patients concomitantly treated
with pioglitazone.
RR 5.4
Messages to take home
• T2DM is associated with an increased incidence and mortality for some
cancers.
•Epidemiologic data support the conclusion that metformin has beneficial
anticancer effects in diabetics or subjects with high BMI or insulin
resistance. Multiple trials are ongoing and should inform the field as to
whether this potential anti-cancer agent truly has benefit.
• Some safety signals have emerged from clinical trials or observational
studies: Further research is needed to clarify these issues.
• Cancer risk should not be a major factor in choosing between available
diabetes therapies. Only for selected patients at high risk for cancer or
recurrences may require careful consideration.
“Prevention avoids
the labour
of being sick”
Thomas Adams, 1618
Diabetes and Cancer: What can we do?
Thanks for your attention
manelmatacases@gmail.com

More Related Content

What's hot

DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMDIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMPraveen Nagula
 
Anti obesity drugs
Anti obesity drugsAnti obesity drugs
Anti obesity drugsDrSahilKumar
 
Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...
Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...
Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...InsideScientific
 
Screening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetesScreening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetesShyam Jadhav
 
9. metabolic syndrome
9. metabolic syndrome9. metabolic syndrome
9. metabolic syndromeMadhumita Sen
 
MAFLD, a new name of an old disease
MAFLD,  a new name of an old diseaseMAFLD,  a new name of an old disease
MAFLD, a new name of an old diseaseEl-Sayed Tharwa
 
Diabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV riskDiabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV riskUsama Ragab
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“Arindam Pande
 
Dpp4i vs sglt2 inhibitors against the motion
Dpp4i vs sglt2 inhibitors  against the motionDpp4i vs sglt2 inhibitors  against the motion
Dpp4i vs sglt2 inhibitors against the motionSujoy Majumdar
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...SYEDRAZA56411
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
 
Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus) Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus) Tarek Al 3reeny
 

What's hot (20)

Dapagliflozin
DapagliflozinDapagliflozin
Dapagliflozin
 
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMDIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
 
Ramadan and diabetes
Ramadan and diabetesRamadan and diabetes
Ramadan and diabetes
 
SGLT-2
SGLT-2 SGLT-2
SGLT-2
 
Nafld suresh ppt
Nafld suresh pptNafld suresh ppt
Nafld suresh ppt
 
Diabetic kidney disease 2021
Diabetic kidney disease 2021Diabetic kidney disease 2021
Diabetic kidney disease 2021
 
Anti obesity drugs
Anti obesity drugsAnti obesity drugs
Anti obesity drugs
 
Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...
Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...
Cardiometabolic Disease Pathophysiology & Novel Therapies for Atherosclerosis...
 
Screening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetesScreening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetes
 
9. metabolic syndrome
9. metabolic syndrome9. metabolic syndrome
9. metabolic syndrome
 
MAFLD, a new name of an old disease
MAFLD,  a new name of an old diseaseMAFLD,  a new name of an old disease
MAFLD, a new name of an old disease
 
Diabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV riskDiabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV risk
 
GLP-1 Agonist
GLP-1 AgonistGLP-1 Agonist
GLP-1 Agonist
 
ADA GUIDELINE.pptx
ADA GUIDELINE.pptxADA GUIDELINE.pptx
ADA GUIDELINE.pptx
 
Diabetes
DiabetesDiabetes
Diabetes
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
Dpp4i vs sglt2 inhibitors against the motion
Dpp4i vs sglt2 inhibitors  against the motionDpp4i vs sglt2 inhibitors  against the motion
Dpp4i vs sglt2 inhibitors against the motion
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
 
Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus) Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus)
 

Similar to Type 2 Diabetes and Cancer

Sitagliptina e proteção em ca diferenciado da tireóide.x
Sitagliptina e proteção em ca diferenciado da tireóide.xSitagliptina e proteção em ca diferenciado da tireóide.x
Sitagliptina e proteção em ca diferenciado da tireóide.xRuy Pantoja
 
Ueda2015 dm cancer_dr.hala aly
Ueda2015 dm  cancer_dr.hala alyUeda2015 dm  cancer_dr.hala aly
Ueda2015 dm cancer_dr.hala alyueda2015
 
Srivastava Rakesh cells Research paper
 Srivastava Rakesh  cells  Research paper Srivastava Rakesh  cells  Research paper
Srivastava Rakesh cells Research paperRakeshSrivastava87
 
Cancer, alzheimers, diabetes – what do all have in common?
Cancer, alzheimers, diabetes – what do all have in common?Cancer, alzheimers, diabetes – what do all have in common?
Cancer, alzheimers, diabetes – what do all have in common?morwenna2
 
cancer &DM proff 26820222 (1).pptx
cancer &DM proff 26820222 (1).pptxcancer &DM proff 26820222 (1).pptx
cancer &DM proff 26820222 (1).pptxMonaAbdelhady3
 
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...National Osteoporosis Society
 
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...CrimsonPublishersIOD
 
SCCHN & Weight FINAL
SCCHN & Weight FINALSCCHN & Weight FINAL
SCCHN & Weight FINALAbby Smith
 
Research Bibliography Assignment
Research Bibliography Assignment Research Bibliography Assignment
Research Bibliography Assignment Nilam Hypio
 
Obesity & endometrial cancer
Obesity & endometrial cancerObesity & endometrial cancer
Obesity & endometrial cancerWafaa Benjamin
 
RunningHead PICOT Question1RunningHead PICOT Question7.docx
RunningHead PICOT Question1RunningHead PICOT Question7.docxRunningHead PICOT Question1RunningHead PICOT Question7.docx
RunningHead PICOT Question1RunningHead PICOT Question7.docxrtodd599
 
Controversies in type 2 diabetes mellitus
Controversies in type 2 diabetes mellitusControversies in type 2 diabetes mellitus
Controversies in type 2 diabetes mellitusPratap Tiwari
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...nephro mih
 
11 271.docx
11 271.docx11 271.docx
11 271.docxwrite12
 
ANGINA: Treatment by Alternative Therapeutic Principal?
ANGINA: Treatment by Alternative Therapeutic Principal?ANGINA: Treatment by Alternative Therapeutic Principal?
ANGINA: Treatment by Alternative Therapeutic Principal?Dr Tarique Ahmed Maka
 

Similar to Type 2 Diabetes and Cancer (20)

Statins and diabetes risk
Statins and diabetes riskStatins and diabetes risk
Statins and diabetes risk
 
Sitagliptina e proteção em ca diferenciado da tireóide.x
Sitagliptina e proteção em ca diferenciado da tireóide.xSitagliptina e proteção em ca diferenciado da tireóide.x
Sitagliptina e proteção em ca diferenciado da tireóide.x
 
Ueda2015 dm cancer_dr.hala aly
Ueda2015 dm  cancer_dr.hala alyUeda2015 dm  cancer_dr.hala aly
Ueda2015 dm cancer_dr.hala aly
 
Iatrogenic diabetes
Iatrogenic diabetesIatrogenic diabetes
Iatrogenic diabetes
 
Srivastava Rakesh cells Research paper
 Srivastava Rakesh  cells  Research paper Srivastava Rakesh  cells  Research paper
Srivastava Rakesh cells Research paper
 
Cancer, alzheimers, diabetes – what do all have in common?
Cancer, alzheimers, diabetes – what do all have in common?Cancer, alzheimers, diabetes – what do all have in common?
Cancer, alzheimers, diabetes – what do all have in common?
 
cancer &DM proff 26820222 (1).pptx
cancer &DM proff 26820222 (1).pptxcancer &DM proff 26820222 (1).pptx
cancer &DM proff 26820222 (1).pptx
 
Strive Teleconf Presentation Oct11 2006
Strive Teleconf Presentation Oct11 2006Strive Teleconf Presentation Oct11 2006
Strive Teleconf Presentation Oct11 2006
 
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
 
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...
 
Nutrition for People with Lung Cancer.pdf
Nutrition for People with Lung Cancer.pdfNutrition for People with Lung Cancer.pdf
Nutrition for People with Lung Cancer.pdf
 
SCCHN & Weight FINAL
SCCHN & Weight FINALSCCHN & Weight FINAL
SCCHN & Weight FINAL
 
Research Bibliography Assignment
Research Bibliography Assignment Research Bibliography Assignment
Research Bibliography Assignment
 
Obesity & endometrial cancer
Obesity & endometrial cancerObesity & endometrial cancer
Obesity & endometrial cancer
 
RunningHead PICOT Question1RunningHead PICOT Question7.docx
RunningHead PICOT Question1RunningHead PICOT Question7.docxRunningHead PICOT Question1RunningHead PICOT Question7.docx
RunningHead PICOT Question1RunningHead PICOT Question7.docx
 
Controversies in type 2 diabetes mellitus
Controversies in type 2 diabetes mellitusControversies in type 2 diabetes mellitus
Controversies in type 2 diabetes mellitus
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...
 
Obesity and Breast cancer
Obesity and Breast cancer Obesity and Breast cancer
Obesity and Breast cancer
 
11 271.docx
11 271.docx11 271.docx
11 271.docx
 
ANGINA: Treatment by Alternative Therapeutic Principal?
ANGINA: Treatment by Alternative Therapeutic Principal?ANGINA: Treatment by Alternative Therapeutic Principal?
ANGINA: Treatment by Alternative Therapeutic Principal?
 

More from Primary Care Diabetes Europe

The Clinical management of type 2 diabetes for the elderly
The Clinical management of type 2 diabetes for the elderlyThe Clinical management of type 2 diabetes for the elderly
The Clinical management of type 2 diabetes for the elderlyPrimary Care Diabetes Europe
 
Diabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskDiabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskPrimary Care Diabetes Europe
 
The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...
The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...
The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...Primary Care Diabetes Europe
 
Clinical management of elderly people with diabetes
Clinical management of elderly people with diabetesClinical management of elderly people with diabetes
Clinical management of elderly people with diabetesPrimary Care Diabetes Europe
 
Treatment perceptions andmisunderstandings with cliniciansin people with diab...
Treatment perceptions andmisunderstandings with cliniciansin people with diab...Treatment perceptions andmisunderstandings with cliniciansin people with diab...
Treatment perceptions andmisunderstandings with cliniciansin people with diab...Primary Care Diabetes Europe
 

More from Primary Care Diabetes Europe (8)

The Clinical management of type 2 diabetes for the elderly
The Clinical management of type 2 diabetes for the elderlyThe Clinical management of type 2 diabetes for the elderly
The Clinical management of type 2 diabetes for the elderly
 
Elderly with Diabetes in Primary Care
Elderly with Diabetes in Primary CareElderly with Diabetes in Primary Care
Elderly with Diabetes in Primary Care
 
Diabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskDiabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease risk
 
The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...
The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...
The 2nd Diabetes Attitudes, Wishes & Needs (DAWN2) study: objectives and meth...
 
Clinical management of elderly people with diabetes
Clinical management of elderly people with diabetesClinical management of elderly people with diabetes
Clinical management of elderly people with diabetes
 
Diabetes & Mental Health in primary care
Diabetes & Mental Health in primary careDiabetes & Mental Health in primary care
Diabetes & Mental Health in primary care
 
Psychosocial impact of diabetes
Psychosocial impact of diabetesPsychosocial impact of diabetes
Psychosocial impact of diabetes
 
Treatment perceptions andmisunderstandings with cliniciansin people with diab...
Treatment perceptions andmisunderstandings with cliniciansin people with diab...Treatment perceptions andmisunderstandings with cliniciansin people with diab...
Treatment perceptions andmisunderstandings with cliniciansin people with diab...
 

Recently uploaded

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 

Recently uploaded (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 

Type 2 Diabetes and Cancer

  • 1. Type 2 Diabetes and Cancer Dr. Manel Mata Family Physician. La Mina Primary Care Centre. Barcelona Family and Community Medicine Teaching Unit. Catalonian Institute of Health. DAP_Cat Group. Institut Universitari d’Investigació en Atenció Primaria IDIAP-Jordi Gol. Barcelona. Spain. RedGDPS (Spanish Network of Primary Care Groups for the Study of Diabetes). www.Redgdps.org
  • 2. Type 2 Diabetes and Cancer Dr. Manel Mata Conflict of interest disclosure: Honoraria from ASTRA-ZENECA, BAYER, BOEHRINGER INGELHEIM, BMS, ESTEVE, GSK, LILLY, MENARINI, MERCK, MSD, NOVARTIS, NOVONORDISK, SANOFI and SERVIER for the participation in Advisory Boards and lectures about the treatment of diabetes.
  • 3. • The relationship between diabetes and cancer • Does antidiabetic treatment have an influence on the risk of cancer ? Type 2 Diabetes and cancer
  • 4. American Diabetes Association American Cancer Society Giovanucci E et al. Diabetes Care. 2010;33(7):1674-85. T2DM is associated with increased risk for some cancers (liver, pancreas, endometrium, colorectal, breast, bladder) and reduced risk for prostate
  • 5. Garg SK et al. Diabetes, Obesity and Metabolism. 2014; 16: 97-110 Increased risk of cancer in diabetic patients Summary of cohorts and case control studies meta-analysis Liver 2.5 Pancreas 2.6 Endometrium 2.2 Breast 1.3 Prostate 0.9
  • 6. Garg SK et al. Diabetes, Obesity and Metabolism. 2014;16:97-110 Men Women All 1.44 1.35 Liver 5.16 6.37 Pancreas 1.67 2.13 Breast -- 1.65 Prostate 1.30 -- Increased cancer mortality in diabetic patients
  • 7. There are numerous considerations when assessing cancer risk between diabetics and non diabetics: • Some cancers of metabolically active organs, such liver and pancreas, may induce the onset of type 2 diabetes •The general pattern of an initial elevated peak in cancer risk at the time of diabetes onset, which is substantially higher than subsequent risk, suggests that many cancers are being diagnosed at or around the time of recognition of diabetes Johnson JA et al. Diabetologia 2012; 55:1607–18
  • 8. Walker JJ et al. Lancet Diabetes Endocrinol 2013; 1: 132–39 Timing of exposure: reverse causality and detection bias Reports from two different population databases have shown an initial spike in the risk of most cancers immediately after the onset of diabetes, followed by a subsequent normalisation of risk 1. Investigation of early cancer symptoms leads to the diagnosis of diabetes (reverse causality) 2. Diagnosis of diabetes can lead to additional clinical investigations, resulting in the identification of cancers (bias in cancer detection) 3. Reverse causality and bias in cancer detection might also be present in the time of initiation for a new drug.
  • 9. Cancer Incidence excluding 1st year aRR Liver 3.50 Pancreas 2.85 Colon 1.56 Breast 1.56 Bladder 0.53 Prostate 0.76 Kidney 0.25 Tayside (Scotland) DART MEMO database 9,577 newly diagnosed T2DM 1993–2004, 19,154 matched non-diabetic comparators National Cancer Register. No significant differences in Any cancer 1.05 (0.93-1.18) Ogunleye AA, Ogston SA, Morris AD, Evans JMM
  • 10. Diabetes and Cancer share common risk factors • Non-modifiable: Aging, Male sex, Race/Ethnicity • Modifiable: Obesity Diet (high calories, red meat, processed foods...) Sedentarism Smoking habit Excessive alcohol consumption Giovannucci E, et al. Diabetes Care 2010; 33: 1674-85 The relationship between type 2 diabetes and cancer is consistent and reasonably strong. Johnson JA & Pollak M. Diabetologia. 2010;53:2086-8 American Diabetes Association American Cancer Society
  • 11. Biological links between Diabetes and Cancer • Hyperinsulinemia • Hyperglycaemia • Chronic inflammation (citokines) • Insulin receptor/insulin-like growth factor I (IGF-I) Axis – Promotion of cell proliferation – Decreased apoptosis Giovannucci E et al. Diabetes Care 2010; 33: 1674-85 American Diabetes Association American Cancer Society
  • 12. Garg SK et al. Diabetes, Obes and Metab. 2014; 16: 97-110 The accumulation of experimental and epidemiological evidence is more consistent with the hyperinsulinaemia hypothesis and less so with the hyperglycaemia hypothesis. Johnson JA & Pollak M. Diabetologia. 2010;53:2086-8
  • 13. Obesity and Endometrial Cancer https://tginnovations.wordpress.com/2013/08/10/you-already-know-how-to-defeat-cancer/
  • 14. • The relationship between diabetes and cancer • Does antidiabetic treatment have an influence on the risk of cancer ? Type 2 Diabetes and cancer
  • 15. Antidiabetic drugs and cancer - Metformin neutral or protective Safety signals: - Sulfonylureas colon - Insulin pancreas, colon - Pioglitazone bladder - Sitagliptin and Exenatide pancreas - Dapagliflozin bladder
  • 16. Although still limited, early evidence suggests that metformin is associated with a lower risk of cancer and that exogenous insulin is associated with an increased cancer risk. Further research is needed to clarify these issues and evaluate if insulin glargine is more strongly associated with cancer risk compared with other insulins. Giovanucci E et al. Diabetes Care. 2010;33(7):1674-85.
  • 17. Considerations when comparing users vs non users: • Confounding by indication: the non-random allocation of all glucose-lowering therapies in observational studies • Accounting for total, and perhaps cumulative drug exposure • Immortal time bias: the period between cohort entry and date of first exposure, during which cancer has not occurred, is misclassified or excluded (not accounted for in the analysis) Johnson JA et al. Diabetologia 2012; 55:1607–18
  • 18. Several observational studies indicate that T2D patients treated with metformin have a lower risk of cancer, but these should be interpreted with caution because of possible confounders, mostly notably confounding by indication. Smith U & Gale EAM. Diabetologia 2010; 53:1541–4 Data from Ranzomized Clinical Trials (meta-analysis) • Improving blood glucose control confers no benefit in cancer risk. • UKPDS 34 reported a not statistically significant 29% reduction in cancer mortality rates with metformin. Johnson JA & Bowker SL et al Diabetologia 2011; 54:25–31 Metformin and cancer
  • 19. Metformin was associated with reduced risk (OR 0.38), while insulin (OR 4.99) and insulin secretagogues (OR 2.52) with increased risk of pancreatic cancer in diabetic patients. Li D et al. Gastroenterology 2009;137:482–8 Case-control study 2004 to 2008 973 pancreatic cancer (259 DM) 863 controls (109 DM. Texas (US)
  • 20. Insulin (HR 1.26) and sulfonylureas (HR 1.38) were associated with increased cancer risk in comparison to metformin, but this differences disapeared after several adjustments Kowall B et al. Diabetes Care 2015 ; 38:59-65 SU and insulin vs metformin German database. N=22,556, 4.8 years
  • 21. Sulfonylureas vs No SU ADOPT trial 1.17 (ns) 6 Cohort studies 1.19 (ns) 10 Case-control studies 1.05 (ns) Thakkar B et al. Metabolism 2013; 62:922-34
  • 22. Metformin vs No Metformin ADOPT trial 1.01 (ns) 9 Cohort studies 0.85 (ns) 13 Case-control studies 0.71 (0.57-0.88) Thakkar B et al. Metabolism 2013; 62:922-34
  • 23. Our results show that metformin may reduce cancer incidence and mortality in patients with diabetes. However, the reduction seems to be of modest magnitude and not affecting all populations equally. Gandini S et al. Cancer Prev Res 2014; 7(9); 867–85 47 studies (65,540 cancers) Metformin vs No Metformin 0.690.90 0.660.45
  • 24. Provinciali N et al. Expert Opin. Drug Saf. 2015; 14(10):1573-1585 Metformin acts as a mitochondrial poison inhibiting complex 1of the mitochondrial respiratory chain. Mitochondrial ATP production is impaired, creating a state of energy restriction.
  • 25. Provinciali N et al. Expert Opin. Drug Saf. 2015; 14(10):1573-1585 Epidemiologic data support the conclusion that metformin has beneficial anticancer effects in diabetics or subjects with high BMI or insulin resistance. Thus far, the evidence from clinical trials stems largely from modulation of biomarkers in a direction consistent with benefit, that is, decreased proliferation or increased apoptosis, in breast and endometrial cancers. Multiple trials are ongoing and should inform the field as to whether this potential anti-cancer agent truly has benefit.
  • 27. Bowker SL et al. Diabetes Care 2006; 29(2):254-8 10.309 T2DM starting sulfonylurea, metformin or insulin monotherapy Saskatchewan database (Canada) 1991-1996. Mean follow-up: 5,4 years (range 1-9) Adjusted HR by age, sex and commorbidity (Chronic Disease Score) Greater cancer mortality with sulfonylureas (1.3) and insulin (1.9) in comparison to Metformin
  • 28. Currie C et al. J Clin Endocrinol Metab 2013; 98: 668–77 UK General Practice Research Database, 2000–2010 84,622 T2DM patients Conclusions: Exogenous insulin therapy was associated with an increased risk of diabetes-related complications, cancer (OR 1.81), and all-cause mortality (OR 2.2). Differences in baseline characteristics between treatment groups should be considered when interpreting these results.
  • 29. Men Women Increased mortality in diabetic patients with cancer (greater in those treated with insulin) Conclusions/interpretation: More intensive diabetes treatment reflects a larger degree of comorbidity at the time of cancer diagnosis and a poorer survival noDM DM no Med DM+OHA DM+INS RR 6.5 426,129 patients with incident cancer, (42,205 with diabetes prior to cancer diagnosis) DM+INS RR 5 Ranc K et al. Diabetologia 2014; 57:927-34
  • 30. The link beetween exogenous insulin and cancer: Insulin has affinity for the IGF-1 receptors expressed by tumor cells Increased insulin, IGF-1, and IGF-2 signaling through the insulin receptor and IGF-1 receptor can induce tumorigenesis by up-regulating the insulin receptor and IGF-1 receptor signaling pathways Gallagher EJ et al. Endocr Pract. 2010;16(5):864-873.
  • 31. 2009 Insulin Glargine and cancer
  • 32. Diabetologia, 26 june 2009 Five original papers and one editorial about cancer and glargine
  • 33. ORIGIN Glargine vs. Standard Care • 1st CV Composite: HR = 1.02 (0.94, 1.11) • 2nd CV Composite: HR = 1.04 (0.97, 1.11) • Death: HR = 0.98 (0.90, 1.08) • Microvascular Composite: HR = 0.97 (0.90, 1.05) • Cancer: HR = 1.00 (0.88, 1.13) • Conversion IFG/IGT to DM: HR = 0.72 (0.58, 0.91) P=0.006 N=12,537; 573 sites; 40 countries; Median Follow-up: 6.2 years The ORIGIN trial Investigators. 10.1056/NEJMoa1203858 en NEJM.org Outcome Reduction with Initial Glargine INtervention
  • 34. Owens DR. Diabetes Care 2012; 35:2426-8 On the basis of the findings from epidemiological studies and the latest pharmacokinetic data the chapter on whether insulin glargine per se is an independent risk factor for cancer should now be closed.
  • 35. 17.9.10 FDA alert 9.6.11 Withdrawal in France and Germany 15.6.11 FDA Warning 21.7.11 EMA Warning ………. 5.12.14 Observational study of 6 population databases (5,9 M patients-year): No increase 2010 Pioglitazone and bladder cancer
  • 36. N= 1,491,060, 40-79 year-old T2DM on antidiabetic treatment, 155,535 on Pioglitazone. Follow-up 42 months (2006-2009) 175 bladder cancer cases in Pio users vs 1,841 in nonPio users 49.4 vs 42.8 per 100,000 person-years (aRR 1.22) HR Any exposure 1.22 Exposure >24 months 1.36 Cumulative dose >28,000 mg 1.75 EMA 21/07/11 • The benefits outweigh the risks in those patients responding well to pioglitazone • After three to six months of treatment, discontinue pioglitazone in patients not having sufficient benefit • Discontinue treatment with pioglitazone in those patients who have, or have had, bladder cancer, include those who are awaiting investigation of haematuria. Neumann A et al. Diabetologia 2012; 55:1953-62
  • 37. Observational study of 6 population databases (5.9 M patient-years) 3,248 incident bladder cancer cases RR (95% CI)* Pioglitazone Men 1.01 (0.97-1.06) Women 1.04 (0.97-1.11) Rosiglitazone Men 1.01 (0.98-1.03) Women 1.00 (0.94-1.07) *adjusted for age, calendar year, diabetes duration, smoking and any ever use of the drug There was no evidence for any association between cumulative exposure to pioglitazone and bladder cancer in men (HR 1.01) or in women (RR 1.04) after adjustment for age, calendar year, diabetes duration, smoking, and any ever use of pioglitazone. Levin D. Diabetologia. 2015 Mar;58(3):493-504. Diabet Med. 2015;32(3):305-13.
  • 39. Butler P & Gale E Nauck M Diabetes Care Publish Ahead of Print, published online May 6, 2013 To date, the FDA has not seen a convincing signal between the use of GLP-1 or DPP-4 agents and pancretic cancer, but it continues to monitor new findings and carefully evaluates them. JUNE 2013
  • 40. Incretins and Pancreatic Ductal Adenocarcinoma One study of eight necropsies (7 sitagliptin and 1 exenatide) described enlargement of the pancreas, chronic inflammation and dysplasia (premalignant) that might favor the long term appearance of ductal cancer Butler AE et al. Diabetes 2013; 62: 2595-604 Plausible model: Stimulation of GLP1 receptors might proliferate exocrine ducts accelerating dysplasia in patients with a chronic low-grade pancreatic inflammation Butler A & Gale E, Diabetes Care. published online May 6, 2013 The FDA and the EMA agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. Egan AG et al. NEJM 2014; 370(9) Pub Online 27 february 2014
  • 41. TECOS (Sitagliptin)3 Placebo n=7,339 Sitagliptin n=7,332 p value Pancreatic cancer 14 (0.2%) 9 (0.1%) 0.32 DPP4 inhibitors in the cardiovascular outcomes trials Pancreas cancer SAVOR TIMI53 (Saxagliptin)2 Placebo (N=8,212) Saxagliptin (N=8,280) p value Cancer (%) 4.4 4.0 0.15 Pancreatic Cancer, n (%) 12 (0.1) 5 (0.06) 0.095 EXAMINE (Alogliptin)1 No pancreatic cancer cases in both arms 1. White et al. NEJM 2013 2. Scirica et al. NEJM 2013 3. Green et al. NEJM 2015
  • 42. http://professional.diabetes.org/Presentations_Details.aspx?session=4740 ELIXA study lixisenatide vs placebo Pancreatic neoplasm during the study n (%) Placebo N=3032 Lixisenatide N=3031 Events adjudicated as malignant by PSAC Patients with events Related Possibly related Unlikely related Not related 9 (0.3) 0 2 (<0.1) 3 (<0.1) 4 (0.1) 3 (<0.1) 0 0 2 (<0.1) 1 (<0.1) Events adjudicated as benign by PSAC Patients with events 0 1 (<0.1) Events with insufficient documentation Patients with events 1 (<0.1) 1 (<0.1) PSAC, Pancreatic Safety Assessment Committee
  • 44. Malignancy (continued) *Incidence rate ratio = 1.047 (95% CI: 0.702, 1.579) DAPA=dapagliflozin Johnsson K et al. Diabetologia 2012;55(Suppl1)743-P SGLT2 inhibitors (Dapagliflozin) and risk of cancer EMA 12/11/12 A causal relationship between dapagliflozin and bladder cancer is unlikely. As a precautionary measure, dapagliflozin is not recommended for use in patients concomitantly treated with pioglitazone. RR 5.4
  • 45. Messages to take home • T2DM is associated with an increased incidence and mortality for some cancers. •Epidemiologic data support the conclusion that metformin has beneficial anticancer effects in diabetics or subjects with high BMI or insulin resistance. Multiple trials are ongoing and should inform the field as to whether this potential anti-cancer agent truly has benefit. • Some safety signals have emerged from clinical trials or observational studies: Further research is needed to clarify these issues. • Cancer risk should not be a major factor in choosing between available diabetes therapies. Only for selected patients at high risk for cancer or recurrences may require careful consideration.
  • 46. “Prevention avoids the labour of being sick” Thomas Adams, 1618 Diabetes and Cancer: What can we do?
  • 47. Thanks for your attention manelmatacases@gmail.com